They may only make structure/function claims accompanied by a disclaimer stating these claims have not been evaluated by the FDA
(PubMed) Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ
Advanced periodontal disease also leads to tooth mobility, which is when the tooth becomes loose in its socket
Europe Glucagon-Like Peptide-1 Agonists Market Trends and Insights The dulaglutide segment occupies the highest market share in the Europe Glucagon-Like Peptide-1 Agonists Market in the current year The dulaglutide segment holds the highest share in the Europe Glucagon-Like Peptide-1 Agonists Market in the current year and is expected to register a CAGR of about 8.3% over the forecast period
The FDA ended compounding discretion for tirzepatide in March 2025, maintaining discretion for semaglutide
Known by its brand names, Zepbound and Mounjaro, tirzepatide was initially introduced as a treatment for type 2 diabetes